The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 23, 2021
Filed:
May. 08, 2020
Applicant:
Neurocrine Biosciences, Inc., San Diego, CA (US);
Inventors:
Christopher F. O'Brien, San Diego, CA (US);
Haig P. Bozigian, San Diego, CA (US);
Assignee:
Neurocrine Biosciences, Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4745 (2006.01); A61K 31/495 (2006.01); A61P 25/14 (2006.01); A61K 31/4375 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/4525 (2006.01); A61K 31/4709 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4375 (2013.01); A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/4525 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61P 25/14 (2018.01); A61K 31/495 (2013.01);
Abstract
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.